SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
https://doi.org/10.20996/1819-6446-2011-7-1-70-74
Abstract
A role of angiotensin-converting enzyme (ACE) inhibitors in cardiovascular diseases treatment and prevention is discussed. Some large randomized clinical trials are analyzed. Physical and chemical properties of drugs and its evidence base are considered among possible factors of ACE inhibitors choice. A problem of ACE inhibitor choice is also discussed in context of secondary prevention of cardiovascular complications in arterial hypertension and after myocardial infarction. It is concluded that the choice of any drug for cardiovascular disease treatment is mainly determined by its evidence base.
About the Authors
S. R. Gilyarevskiy
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
V. A. Orlov
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
M. V. Golshmid
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
G. Yu. Zakharova
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
I. I. Sinitsina
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
References
1. Garg R., Yusuf S; Collaborative Group of ACE Inhibitor Trials. Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450—1456.
2. Gavazzi A., Marioni R., Campana C., et al. Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure. J Hypertens 1994;12:S89—93.
3. Bach R., Zardini P. Long-acting angiotensin-converting enzyme inhibition: once daily lisinopril versus twice-daily captopril in mild-to-moderate heart failure. Am J Cardiol 1992;70:70C—77C.
4. Borghi C., Ambrosinoni E.; Survival of Myocardial Infarction Long-term Evaluation- 2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003;145:80—87.
5. Giles T.D., Katz R., Sullivan J.M., et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989;13:1240—1247.
6. Foy S.G., Crozier I.G., Turner J.G., et al. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the “PRACTICAL” study). Am J Cardiol 1994;73:1180—1186.
7. Wienbergen H., Schiele R., Gitt A., et al. Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol 2002;90:1045—1049.
8. Pilote L., Abrahamowicz M., Rodrigues E., et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: A class effect? Ann Intern Med 2004;141:102—112.
9. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411—1420.
10. Sica D.A. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: Are their benefits a class effect or do individual agents differ? Curr Opin Nephrol Hypertens 2001;10:597—601.
11. Tsikouris J.P., Suarez J.A., Meyerrose G.E., et al. Questioning a class effect: Does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol 2004;44:150—157.
12. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145—153.
13. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782—788.
14. Braunwald E., Domanski M.J., Fowler S.E., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058—2068.
15. Mancini G.B., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258—265.
16. Pitt B., O'Neill B., Feldman R., et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and pre-served left ventricular function. Am J Cardiol 2001;87:1058—1063.
17. Torp-Pedersen C., Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999;354:9—12.
18. Dagenais G.R., Pogue J., Fox K., et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581—588.
19. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-616.
20. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981—2997.
21. Bangalore S., Messerli F.H., Franklin S.S. et al. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. Eur Heart J 2009;30:1395-401.
22. Ruggenenti P., Perna A., Ganeva M., et al. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006;17:3472—3481.
23. Mitchell G.F., Dunlap M.E., Warnica W., et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007;49:1271—1277.
24. Conen H., Brunner H.R. Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. Am Heart J 1993;125:1525—1531.
25. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670—1676.
26. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821—828.
27. Pedersen O.D., Bagger H., Kober L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376—380
Review
For citations:
Gilyarevskiy S.R., Orlov V.A., Golshmid M.V., Zakharova G.Yu., Sinitsina I.I. SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW. Rational Pharmacotherapy in Cardiology. 2011;7(1):70-74. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-1-70-74
Views:
655
Email this article 